All In Biotech

Drug Trial Radar · NCT06788522

The Effects of Orexin Antagonism on Fear Extinction in PTSD

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 40,120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

40,120

Planned (sponsor's estimate)

Start

Jul 1, 2026

Primary completion

Mar 1, 2032

Study completion Jun 30, 2032

Sponsor

Lead sponsor
VA Office of Research and DevelopmentFederal agency
Sponsor type
Federal agency
First posted
Jan 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

PTSD affects approximately 22% of Veterans who have served in Iraq and Afghanistan. Symptoms of PTSD may include re-experiencing, avoidance of trauma reminders, negative thoughts or feelings, and hyperarousal, such as increased startle reactivity and disturbed sleep. Treatments for PTSD are based on fear extinction principles in which individuals are repeatedly exposed a feared cue in the absence of danger, resulting in diminishing physiological reactions, a process believed to underlie recovery from PTSD. Studies suggest that orexin, a wake-promoting neuropeptide, may enhance fear extinction. This study will examine whether suvorexant, a selective orexin-receptor antagonist, will enhance fear extinction in Veterans with PTSD and insomnia. Finding a role for orexins in fear extinction will support the rationale for its further evaluation in the treatment of PTSD. Suvorexant is an accessible, safe medication that has been well-established in treating insomnia. It has outstanding promise for treating common and distressing symptoms in Veterans with PTSD.

Conditions

  • Insomnia
  • PTSD

Interventions

  • SuvorexantDrug

    Suvorexant pills (10-20 milligrams)

  • PlaceboDrug

    Matching placebo pills

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. EnrollmentTime frame: Month 4-23
  2. Medication AdherenceTime frame: Month 4-23
  3. Side effect reportsTime frame: Month 4-23
  4. Post-randomization drop outTime frame: Month 4-23
  5. Fear conditioning and extinctionTime frame: Month 4-23
  6. Rates of technical malfunctionTime frame: Month 4-23
  7. Electrodermal ActivityTime frame: Years 2-7

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • San Francisco VA Medical Center, San Francisco, CA

    San Francisco, California · Recruiting

  • Ralph H. Johnson VA Medical Center, Charleston, SC

    Charleston, South Carolina · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.